In This Section

Embargo Policy

Please read the following information closely regarding the embargo policy for the AACR Annual Meeting 2026. You may contact Julia Gunther at [email protected] or Kathleen Medora at [email protected] with additional questions.

Embargo Policy

Abstracts submitted to the AACR Annual Meeting are confidential and embargoed until the AACR publishes the abstract in the AACR’s Online Itinerary Planner. The abstract release schedule is as follows:

  • Full regular abstracts – i.e., TITLES AND TEXT – will be published on March 17, 2026, at 4:30 p.m. ET.
  • Late-breaking and clinical trials abstract TITLES ONLY (no text) will be published on March 17, 2026, at 4:30 p.m. ET.
  • Late-breaking and clinical trials abstract TEXT will be published on April 17, 2026, at 12 p.m. PT/3 p.m. ET.
  • Poster presentations will be available on the virtual meeting platform on April 17, 2026, at 12 p.m. PT/3 p.m. ET.

Press Program

Abstracts selected for the official AACR Annual Meeting Press Program are embargoed until the date and time of presentation, either at an official press conference or in a scientific session. Press program abstracts will be made publicly available once the embargo lifts.

Institutions or companies planning to promote abstracts that are selected for the official AACR Annual Meeting​​​​​​ press program must contact Julia Gunther at [email protected] to ensure all embargo policies are followed. The AACR​​​​​​​ public relations team will contact presenters directly if their abstract is selected for the press program.

OUTSIDE PRESS RELEASES

Public information officers or public relations firms representing academia or industry with abstracts in the meeting can issue press releases on information that is publicly available via the AACR’s Online Itinerary Planner, according to the schedule above. 

  • A press release that includes data from a regular abstract may be issued on March 17, 2026, at 4:30 p.m. ET, when the AACR publishes that information online.
  • A press release that includes the title and logistical presentation details only (presenter, session information, etc.) of a late-breaking or clinical trials abstract may be issued on March 17, 2026, at 4:30 p.m. ET, when the AACR publishes that information online. These title-only press releases must not include any data or information from the abstract.
  • A press release that includes data from a late-breaking or clinical trials abstract may be issued on April 17, 2026, at 12 p.m. PT/3 p.m. ET, when the AACR publishes that information online.
  • For posters: A press release that includes full data from a poster (beyond what is available in the abstract) may be issued at 12 p.m. PT/3 p.m. ET on Friday, April 17, when e-posters are made available to meeting attendees through the virtual meeting platform.
  • For oral presentations: A press release that includes full data from an oral presentation (beyond what is available in the abstract) may be issued at the beginning of the session where the study will be presented.

Once an abstract is accepted for presentation at the AACR Annual Meeting, the AACR holds the copyright to the abstract. The abstract may not be published or reproduced elsewhere.

EXCEPTIONS TO THE EMBARGO POLICY

EMBARGO VIOLATIONS: PRESENTERS AND PUBLIC RELATIONS

Presenters, their companies/institutions, and affiliated public relations representatives who break the AACR’s embargo policy as outlined above could jeopardize an abstract’s placement in the scientific program and press events.

EMBARGO VIOLATIONS: MEDIA

Individuals registered as press for the AACR Annual Meeting 2026 agree to abide by all embargoes. In advance of the meeting, the AACR may provide abstracts, press releases, and other materials under embargo to facilitate accurate and comprehensive reporting. Failure to abide by the AACR’s embargoes may result in removal from AACR pre-embargo press lists and dismissal from current and future AACR meetings.